

U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 35

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Midwest Division - LSH, LLC (d/b/a Lee's Summit Hospital)</p> <p>2. 2100 S.E. Blue Parkway Lee's Summit, MO 64063</p>	<p>In accordance with letter dated <b>August 11, 2015,</b></p> <p>3. License number 24-24660-01 is amended in its entirety to read as follows:</p> <p>4. Expiration date March 31, 2022</p> <p>5. Docket No. 030-29074 Reference No.</p>
---	--

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1 curie
D. Any byproduct material permitted by 10 CFR 31.11	D. Prepackaged Kits	D. 2 millicuries

9. Authorized use:
- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
  - B. Any imaging and localization study permitted by 10 CFR 35.200.
  - C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
  - D. In vitro studies.

CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 2100 S.E. Blue Parkway, Lee's Summit, Missouri
- 11. The Radiation Safety Officer (RSO) for this license is Aaron M. Lewis, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
24-24660-01

Docket or Reference Number  
030-29074

**Amendment No. 35**

<u>Authorized Users</u>	<u>Material and Use</u>
William M. Chase, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Craig M. Bruner, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Douglas W. Nemmers, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Michael B. Parsa, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Jeffrey R. Conaway, M.D.	10 CFR 35.100, 35.200, and 35.300.
John F. Eurich, M.D.	10 CFR 35.100, 35.200, and 35.300.
Kelly Hart, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Rick Moritz, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Sarah L. Sherard, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Donald J. Stallard, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Daniel H. Dunker, M.D.	10 CFR 35.200.
James E. Sear, M.D.	10 CFR 35.200.
Michael Brian Robertson, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the use of sodium iodide I-131), and 31.11.
Bradley McInay, M.D.	10 CFR 35.100, 35.200, 35.300, and 31.11.
Vandana Halder, M.D.	10 CFR 35.100, 35.200, and 35.300.
Leo J. Splitter, M.D.	10 CFR 35.100, 35.200, and 35.300.
Craig B. McClure, M.D.	10 CFR 35.100, and 35.200.
Robert A. Wood, Jr., M.D.	10 CFR 35.100, 35.200, and 35.300.
Jason Eric Himmel, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Michael J. Brigg, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the use of sodium iodide I-131).
Nathaniel R. Jewell, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the use of sodium iodide I-131).
Richard Cronemeyer, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
24-24660-01Docket or Reference Number  
030-29074**Amendment No. 35**Authorized UsersMaterial and Use

Christopher McKinney, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

Aaron M. Lewis, M.D.

10 CFR 35.100, 35.200, and 35.300.

Brian A. Fletcher, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the use of sodium iodide I-131).

Nathan S. Johnson, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the use of sodium iodide I-131).

Amy P. Oberhelman, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

Sujit R. Gandhari, M.D., M.P.H.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

Daniel T. Finn, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

Curtis T. Selser, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

**Mary Mitchell, M.D.****10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).**

13. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."


**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**License Number  
24-24660-01Docket or Reference Number  
030-29074**Amendment No. 35**

14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated September 29, 2011 (with attachments) (ML112730520).

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date NOV 18 2015

By

  
Cassandra F. Frazier  
Materials Licensing Branch  
Region III